30 Aug, 2024 Detailed Results from the HELIOS-B Phase 3 study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Presented at the ESC Congress 2024 and Published in The New England Journal of Medicine
Posted at 06:00h
in Capella
Detailed results from the Phase 3 HELIOS-B study of vutrisiran, an RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in a Hot Line session at the European Society of Cardiology Congress (ESC) 2024 and simultaneously published in The New England Journal of Medicine.
